Comparer des méthodes

	Échelle d'évaluation de la sévérité du risque suicidaire de Columbia (C-SSRS)	Inventaire de dépression de Beck-II (BDI-II)
Domaine	Psychologie clinique	Psychologie clinique
Famille	Process / pipeline	Process / pipeline
Année d'origine	2008	1996
Auteur d'origine	Kelly Posner	Aaron T. Beck
Type	Clinician-administered interview scale	Self-report questionnaire
Source fondatrice	Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., & Shen, S. (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry, 168(12), 1266–1277.	Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck Depression Inventory (2nd ed.). San Antonio, TX: The Psychological Corporation. ISBN: 9780151840045
Alias	C-SSRS, Columbia Suicide Severity Rating Scale	BDI-II, Beck Depression Inventory Second Edition
Apparentées	4	4
Résumé	The Columbia-Suicide Severity Rating Scale is a brief clinician-administered assessment of suicide risk developed by Kelly Posner and colleagues at Columbia University to address limitations in prior screening tools. First published in the American Journal of Psychiatry in 2011, the C-SSRS has become the FDA-endorsed standard for monitoring suicidal ideation and behavior in antidepressant, anticonvulsant, and neuropsychiatric medication trials. The scale assesses both suicidal ideation (frequency and intensity) and suicidal behavior (attempts, preparatory acts) over defined time windows, providing structured risk stratification.	The Beck Depression Inventory-II is a 21-item self-report instrument designed to assess the presence and severity of depressive symptoms in adolescents and adults. Originally published by Aaron T. Beck in 1961 and revised significantly in 1996, the BDI-II is one of the most widely used depression assessment tools in clinical psychology and psychiatry. It is copyrighted and distributed by Pearson Assessments, and measures both cognitive and somatic symptoms of depression across a two-week timeframe.